Expert Briefing on Biotech Stocks -- Nanosphere, Vanda Pharma, Synta Pharma, Halozyme Therapeutics, and Isis Pharma

Editor Note: For more information about this release, please scroll to bottom.

Aug 14, 2014, 09:30 ET from Investor-Edge

LONDON, August 14, 2014 /PRNewswire/ --

On Wednesday, August 13, 2014, the NASDAQ Composite ended at 4,434.13, up 1.02%, the Dow Jones Industrial Average finished the day 0.55% higher at 16,651.80, and the S&P 500 closed at 1,946.72, up 0.67%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 707.08, up 1.15%, with the index also advancing 4.55% in the previous three months. Investor-Edge has initiated coverage on the following equities: Nanosphere Inc. (NASDAQ: NSPH), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), Synta Pharmaceuticals Corporation (NASDAQ: SNTA), Halozyme Therapeutics Inc. (NASDAQ: HALO), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS). Free research on these five companies can be accessed at:

On Wednesday, shares in Nanosphere Inc. recorded a trading volume of 0.92 million shares, lower than its three months average volume of 1.10 million shares. The stock edged 0.22% higher, to end the day at $0.96, and registered an intraday range of $.0.94 and $0.99. Although Nanosphere Inc.'s shares have surged 7.88% in the previous three trading sessions, it has plummeted 35.56% in the last three months and 58.07% on YTD basis. The stock is trading below its 50-day and 200-day moving averages of $1.39 and $1.93, respectively. Furthermore, shares of Nanosphere Inc. have a Relative Strength Index (RSI) of 27.89. Sign up and read the free notes on NSPH at:

Vanda Pharmaceuticals Inc.'s stock gained 2.72%, to close Wednesday's session at $13.22, after oscillating between $12.77 and $13.29. The stock recorded a trading volume of 0.62 million shares, below its three months average volume of 0.76 million shares. Over the last three trading sessions and previous three months, Vanda Pharmaceuticals Inc.'s shares have surged 9.62% and 22.63%, respectively. Also, from the beginning of 2014, the stock has gained 6.53%. The stock is trading above its 200-day moving average of $12.96, while the 200-day moving average is below Vanda Pharmaceuticals Inc.'s 50-day moving average of $14.21. Further, the stock has an RSI of 41.54. The complimentary notes on VNDA can be downloaded as in PDF format at:

Synta Pharmaceuticals Corp.'s stock finished Wednesday's session 0.50% lower at $4.01. A total of 1.20 million shares were traded, which was below its three months average volume of 1.57 million shares. The stock moved between $3.99 and $4.05 during the session. Synta Pharmaceuticals Corp.'s shares have fallen by 0.50% in the last three trading sessions and 6.74% in the previous three months. Additionally, the stock has declined 23.47% since the beginning of 2014. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $4.74 is greater than its 50-day moving average of $4.18. Synta Pharmaceuticals Corp.'s stock has an RSI of 47.01. Register for free on Investor-Edge and access the latest research on SNTA at:

On Wednesday, shares in Halozyme Therapeutics Inc. traded between $9.80 and $10.23 before ending the session 0.10% lower at $9.89. The stock reported a trading volume of 1.17 million shares, below its three months average volume of 1.80 million shares. Halozyme Therapeutics Inc.'s shares have advanced 1.64% in the previous three trading sessions and 23.01% in the last three months. However, the stock has lost 34.02% on YTD basis. The stock is trading above its 50-day moving average of $9.54. Moreover, shares of Halozyme Therapeutics Inc. have an RSI of 56.56. The complete research on HALO is available for free at:

On Wednesday, Isis Pharmaceuticals Inc.'s stock advanced 4.19%, to close the day at $35.84. The stock recorded a trading volume of 1.51 million shares, below its three months average volume of 2.41 million shares. The stock oscillated between $34.38 and $35.85 during the session. Over the last one month and over the past three months, Isis Pharmaceuticals Inc.'s shares have surged 16.25% and 42.85%, respectively. However, the stock has lost 10.04% since the start of this year. The company's shares are trading above their 50-day moving average of $32.29, while the 50-day moving average is below Isis Pharmaceuticals Inc.'s 200-day moving average of $37.77. Additionally, the stock has an RSI of 61.72. Free in depth research on ISIS is available at:


At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.




1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at]

5. For any urgent concerns or inquiries, please contact us at compliance [at]

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge